Anavex Life Sciences Corp. (NASDAQ:AVXL) finished Friday with a subtraction of -$0.23 to close at $8.82, a downside of -2.54 percent. An average of 1,569,880 shares of common stock have been traded in the last five days. There was a gain of $0.60 in the past week, and it reached a new high 7 times over the past 12 months. The last 20 days have seen an average of 893,805 shares traded, while the 50-day average volume stands at 957,854.
AVXL stock has increased by 4.38% in the last month. The company shares reached their 1-month lowest point of $7.58 on 08/08/23. With the stock rallying to its 52-week high on 02/07/23, shares of the company touched a low of $7.44 and a high of $15.24 in 52 weeks. It has reached a new high 9 times so far this year and lost -4.75% or -$0.44 in price. In spite of this, the price is down -42.13% from the 52-week high.
Insider Transactions
AVXL stock investors should be aware that Anavex Life Sciences Corp. (AVXL) stock had its last reported insider trading activity 45 days ago on Jun 28.
Valuation Metrics
Anavex Life Sciences Corp. (AVXL) stock’s beta is 0.66. Other valuation ratios to consider include the price-to-book (PB) ratio at 4.77.
Financial Health
The quick ratio of Anavex Life Sciences Corp. for the three months ended June 29 was 11.40, and the current ratio was 11.40, indicating that the company is able to meet its debt obligations. Further, the company has a long term debt to equity ratio of 0.00 and a total debt to equity ratio of 0.00 for the quarter ending June 29. Its gross profit as reported stood at $3.37 million compared to revenue of $50.99 million.
For investors, determining the potential profitability of the investment also depends on the performance of the company’s management. In the past 12 months, Anavex Life Sciences Corp.’s return on assets was -34.00%.
Earnings Surprise
In the quarter under review, the net income was down than the previous quarter. The company posted a net income of -$11.28 million in the quarter, while revenues of -$13.11 million were grew 100.0%. The analyst consensus anticipated Anavex Life Sciences Corp.’s latest quarter earnings to come in at -$0.17 per share, but it turned out to be -$0.14, a 17.60% surprise. For the quarter, EBITDA amounted to -$13.53 million. At the end of the quarter ending June 29, Anavex Life Sciences Corp.’s stock balance sheet showed total liabilities of 11.05 million. Shareholders own equity worth $81.95 million.
Technical Picture
From a technical analysis perspective, let’s take a brief look at Anavex Life Sciences Corp. (AVXL) price momentum. RSI 9-day as of the close on 11 August was 58.39%, suggesting the stock is Neutral, with historical volatility in this time frame at 94.76%.
As of today, AVXL’s price is $8.59 +7.30% or $0.60 from its 5-day moving average. AVXL is currently trading +4.75% higher than its 20-day SMA and -4.75% lower than its 100-day SMA. However, the stock’s current price level is -4.55% below the SMA50 and -25.06% below the SMA200.
The stochastic %K and %D were 70.84% and 63.46%, respectively, and the average true range (ATR) was 0.50. With the 14-day stochastic at 53.67% and the average true range at 0.45, the RSI (14) stands at 56.59%. The stock has reached 0.65 on the 9-day MACD Oscillator while the 14-day reading was at 0.82.
Analyst Ratings
Cantor Fitzgerald downgraded Anavex Life Sciences Corp. (NASDAQ: AVXL) to a a Neutral rating in its most recent analyst report. Previously, the stock was rated as an Overweight. The consensus rating for Anavex Life Sciences Corp. (AVXL) among analysts is Buy. According to current brokerage recommendations, 0 brokerage firms advise that investors sell AVXL, while 0 suggest investors hold. There are 0 analysts who rate the stock as underweight. The stock is rated overweight by 0 analysts, while 4 others rate it as a “buy”.
